The EPS beat and cash runway extension are positive but the stock remains a binary event play on ALTITUDE-AD topline results in late 2026. Monitor for any early data disclosures or enrollment updates that could derisk the program. The EBD option exercise in Q2 2026 may provide a near-term catalyst.
Price Chart
Executive Summary
Acumen Pharmaceuticals reported Q1 2026 EPS of -$0.33 (GAAP) vs consensus of -$0.46, a 28.3% beat, with net loss narrowing to $20.7M from $28.8M YoY. Cash balance increased to $128.4M following a $35.75M private placement, funding operations into early 2027. The stock will move on the EPS beat and cash runway extension, but the primary catalyst remains the ALTITUDE-AD Phase 2 topline results expected in late 2026.
Key Financial Metrics
Key Facts
- Q1 2026 GAAP EPS -$0.33 vs consensus -$0.46 (28.3% beat)
- Net loss $20.7M vs $28.8M YoY, improved 28.1%
- Cash, equivalents and marketable securities $128.4M as of Mar 31, 2026, up from $116.9M at Dec 31, 2025
- Private placement in March 2026 raised $35.75M in gross proceeds
- R&D expenses fell to $16.5M from $25.3M YoY due to lower manufacturing and CRO costs
- ALTITUDE-AD Phase 2 topline results expected in late 2026
- Option to license up to two EBD program candidates expected in Q2 2026
- IND filing for lead EBD candidate targeted for mid-2027
Financial Impact
EPS beat of $0.13 vs consensus; net loss improved by $8.1M YoY; cash runway extended into early 2027
Risk Factors
- ALTITUDE-AD Phase 2 failure would likely wipe out most of the company's value
- Cash runway only into early 2027 — additional financing likely needed before results
- Pre-revenue biotech with no approved products; high clinical and regulatory risk
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3292642 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 today | S-3 | $2.27 | awaiting T+20 | — | $2.27 (+0.01%) |
Oct 26, 2026 today | 8-K | $2.07 | awaiting T+20 | — | $2.27 (+9.71%) |
Oct 26, 2026 today | Press Release | $2.05 | awaiting T+20 | — | $2.27 (+10.73%) |
Oct 22, 2026 4d ago | Press Release | $2.06 | awaiting T+20 | — | $2.27 (+10.19%) |
Oct 19, 2026 7d ago | Press Release | $2.02 | awaiting T+20 | — | $2.27 (+12.66%) |
Sep 16, 2026 5w ago | 8-K | $2.61 $1.82 | ▼ −30.46% | ▼ −33.64% | $2.27 (−13.03%) |
Aug 12, 2026 10w ago | Institutional Cluster | $2.51 $2.86 | ▲ +13.94% | ▲ +15.84% | $2.27 (−9.56%) |
Aug 12, 2026 10w ago | 8-K | $2.51 $2.86 | ▲ +13.94% | ▲ +15.84% | $2.27 (−9.56%) |
Aug 12, 2026 10w ago | Press Release | $2.51 $2.86 | ▼ −13.94% | ▼ −15.84% | $2.27 (+9.56%) |
Jun 17, 2026 18w ago | Insider Cluster | $2.26 $2.17 | ▼ −3.98% | ▼ −4.52% | $2.27 (+0.44%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers